Evidence map›Paper›PMID 19406957›Full record

Trial reportClinical journal of the American Society of Nephrology : CJASN2009

Hepcidin--a potential novel biomarker for iron status in chronic kidney disease.

Joshua Zaritsky, Brian Young, He-Jing Wang, Mark Westerman, Gordana Olbina, Elizabeta Nemeth, Tomas Ganz, Seth Rivera, Allen R Nissenson, Isidro B Salusky

Open access · greenAbstract readClinical TrialValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
137citing papers in PubMed, 2 pooled it
12.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

137 citing papers in PubMed, 2 syntheses or guidelines pooled it, 349 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Article

77 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Joshua ZaritskyDepartment of Pediatrics, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA. jzaritsky@mednet.ucla.edu
Brian Young
He-Jing Wang
Mark Westerman
Gordana Olbina
Elizabeta Nemeth
Tomas Ganz
Seth Rivera
Allen R Nissenson
Isidro B Salusky
University of California, Los Angeles · USIntrinsic LifeSciences (United States) · US

Funding

The role of erythroferrone in iron homeostasis and in iron-loading anemiasR01DK065029 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GANZ, TOMAS · 2004 to 2017
$4.9M
ROLE OF PTH IN RENAL OSTEODYSTROPHYR01DK067563 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SALUSKY, ISIDRO B. · 2005 to 2009
$1.9M
The Link Between Anemia of Inflammation and Host DefenseK08DK074284 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RIVERA, SETH · 2005 to 2009
$610k
NIDDK NIH HHS 1K08DK074284-01NIDDK NIH HHS 5R01DK067563-04NIDDK NIH HHS K08 DK074284NIDDK NIH HHS R01 DK065029NIDDK NIH HHS R01 DK067563
6 · The paper itself

Abstract

BACKGROUND AND

objectivesHepcidin is a key regulator of iron homeostasis, but its study in the setting of chronic kidney disease (CKD) has been hampered by the lack of validated serum assays. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This study reports the first measurements of bioactive serum hepcidin using a novel competitive ELISA in 48 pediatric (PCKD2-4) and 32 adult (ACKD2-4) patients with stages 2 to 4 CKD along with 26 pediatric patients with stage 5 CKD (PCKD5D) on peritoneal dialysis.

resultsWhen compared with their respective controls (pediatric median = 25.3 ng/ml, adult = 72.9 ng/ml), hepcidin was significantly increased in PCKD2-4 (127.3 ng/ml), ACKD2-4 (269.9 ng/ml), and PCKD5D (652.4 ng/ml). Multivariate regression analysis was used to assess the relationship between hepcidin and indicators of anemia, iron status, inflammation, and renal function. In PCKD2-4 (R(2) = 0.57), only ferritin correlated with hepcidin. In ACKD2-4 (R(2) = 0.78), ferritin and soluble transferrin receptor were associated with hepcidin, whereas GFR was inversely correlated. In PCKD5D (R(2) = 0.52), percent iron saturation and ferritin were predictors of hepcidin. In a multivariate analysis that incorporated all three groups (R(2) = 0.6), hepcidin was predicted by ferritin, C-reactive protein, and whether the patient had stage 5D versus stages 2 to 4 CKD.

conclusionsThese findings suggest that increased hepcidin across the spectrum of CKD may contribute to abnormal iron regulation and erythropoiesis and may be a novel biomarker of iron status and erythropoietin resistance.

Indexed as

AdolescentAdultAntimicrobial Cationic PeptidesBiomarkersChildC-Reactive ProteinEnzyme-Linked Immunosorbent AssayErythropoiesisFemaleFerritinsGlomerular Filtration RateHepcidinsHumansIronIron-Binding ProteinsMaleAntimicrobial Cationic PeptidesBiomarkersC-Reactive Proteinferritin receptorFerritinsHAMP protein, humanHepcidinsIronIron-Binding ProteinsReceptors, Cell Surface

Identifiers

PMID19406957
PMCPMC2689881
OpenAlexW2128599675

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.